Cell Viability Assays Market | Growth, Trends and Forecast (2018-2023)
Cell Viability Assays Market - Segmented by Product (Consumable, Instruments and Cell Type), Application, End-User and Geography - Growth, Trends and Forecast (2019 - 2024)

PUBLISHED

OCT 2018

Cell Viability Assays Market - Segmented by Product (Consumable, Instruments and Cell Type), Application, End-User and Geography - Growth, Trends and Forecast (2019 - 2024)

Purchase Report

Cell Viability Assays Market Overview

The global cell viability market is projected to grow at a CAGR of approximately 7.2% during the forecast period (2018-2023). Cell Viability Assays is an assays to determine the ability of organs, cells or tissues to maintain or recover viability. Viability can assay mechanical activity, motility, contraction, etc. Mitotic activity, mechanical activity, and motility are all used throughout a viability assay for this reason. Cell counting using the viability dyes which can provide both the rate of proliferation and also the percentage of viable cells.

Rising Incidence and Prevalence of Chronic and Infectious Diseases Boost the Growth of Cell Viability Assays Market

According to the World Health Organization (WHO), chronic diseases are expected to increase by 57% by 2020. Increased demand for healthcare systems due to chronic diseases has become a major concern. Furthermore, according to WHO in 2014, nearly 4 out of every 5 deaths in the world's developing countries resulted from chronic diseases. CDC states that in 2017, chronic diseases were the leading cause of death and disability in the United States, and 133 million Americans, i.e., 45% of the population, had at least one chronic disease. In addition, the rise of age- and lifestyle-related chronic diseases is increasing demand and spending for healthcare. In the developing market, cancer and heart disease are becoming the main causes of death, as a result of urbanization, sedentary lifestyles, changing diets, rising obesity levels, and widespread availability of tobacco products. As per WHO 2016, China and India had the world’s highest number of diabetes sufferers, at more than 98 million and 65 million individuals, respectively.  Due to the increasing prevalence of chronic diseases, there is a high demand for assays that enable early detection and quick diagnosis, which could prove to be particularly impactful. 

Limitations of the Assays Hindering Cell Viability Assays Market

Some of the methods by which the viability of the cells can be checked are as follows: viability assays can reduce NADH in metabolically active viable cells can reduce tetrazolium compounds into brightly colored formazan products. Also, the aminopeptidase activity present only in viable cells can be measured using a cell-permeable fluorogenic substrate. There are many limitations that are associated with the use of these assays which include the time period to check the viability of the cells and it takes 1-4 hour incubation time which is acting as a limiting factor. Also, there is a lot of interference by reducing compounds, for instance, tetrazolium compounds inactive cells can be reduced in the brightly colored formazan products which can create interference in checking the viability of the cells. The absorbance method of detection used by the  MTT assay and other tetrazolium reduction assays (i.e., MTS, XTT, WST-1, WST-8) is generally less sensitive than fluorescent and luminescent methods for detecting viable cell number.  This lack of sensitivity severely limits the ability to miniaturize the assay for HTS applications.  These reagents exhibit cytotoxic effects and adding the reagent to estimate cell viability may actually be damaging or even killing cells during the course of an experiment. Thus all these limitations are greatly impacting the growth of the market.

North America has the Largest Share in Global Cell Viability Assays Market  

North America is dominating due to various factors like the growing incidence of chronic disease, growth in investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research. Various additional advantages such as the availability of insurance coverage for laboratory testing procedures, rising healthcare and R&D expenditure, and the presence of well-structured distribution channels in the region are also supporting the growth of the market.

Key Developments in the Cell Viability Assays Market

Major companies include Pfizer Inc., Bristol- Myers Squibb, Merck & Co., Boehringer Ingelheim Gmbh, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Gilead Sciences Inc., and Teva Pharmaceuticals among others.

Cell Viability Assays Market Report Summary

Metrics

Details

Industry

Cell Viability Assays Market

Study Period

(2015 – 2023)

Growth Rate

7.2%

Fastest Growing Region

Asia Pacific

Key Developments

Jun 2018: Thermo Fisher Scientific Signs Agreement to Acquire Gatan from Roper Technologies

Companies Covered

GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Gilead Sciences Inc., and Teva Pharmaceuticals among others.

Report Offerings

Cell Viability Assays Market offers latest trends, growth prospects, industry competitiveness, major players, regional share of market and forecast to 2023.

Reasons to Purchase this Report

  • Current and future global cell viability assays market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players.
  • 3-month analyst support along with the Market Estimate sheet in excel.

Customization of the Report

  • This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

1. Introduction

                1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview & Industry Trends

                5.1 Current Market Scenario

                5.2 Porter's five Forces Analysis

                                5.2.1 Bargaining Power of Suppliers

                                5.2.2 Bargaining Power of Consumers

                                5.2.3 Threat of New Entrants

                                5.2.4 Threat of Substitute Products & Services

                                5.2.5 Intensity of Competitive Rivalry

6. Market Dynamics (DROC Analysis)

                6.1 Drivers

                                6.1.1 Rising Incidence and Prevalence of Chronic and Infectious Diseases

                                6.1.2 Growing Availability of Funds for Research

                                6.1.3 Rising Demand for Cell-Based Assays in Research

                                6.1.4 Increasing Focus on the Development of Cell-Based Therapeutics

                6.2 Restraints

                                6.2.1 Limitations of the Assays

                6.3 Opportunities

                6.4 Challenges

7. Market Segmentation

                7.1 By Product

                                7.1.1 Consumables

                                                7.1.1.1 Reagents

                                                7.1.1.2 Assay Kits

                                                                7.1.1.2.1 Tetrazolium Reduction Assay Kits

                                                                7.1.1.2.2 Resazurin Cell Viability Assay Kits

                                                                7.1.1.2.3 Calcein-Am Cell Viability Assay Kits

                                                                7.1.1.2.4 Other Assay Kits

                                                7.1.1.3 Microplates

                                7.1.2 Instruments

                                                7.1.2.1 Automated Cell Counters

                                                7.1.2.2 Flow Cytometers

                                                7.1.2.3 Spectrophotometers

                                                7.1.2.4 Cell Imaging & Analysis Systems

                7.2 By Cell Type

                                7.2.1 Human Cells

                                7.2.2 Animal Cells

                                7.2.3 Microbial Cells

                7.3 By Application

                                7.3.1 Drug Discovery & Development

                                7.3.2 Stem Cell Research

                                7.3.3 Clinical and Diagnostic Applications

                                7.3.4 Other Applications

                7.4 By End User

                                7.4.1 Pharmaceutical & Biotechnology Companies

                                7.4.2 Academic & Research Institutes

                                7.4.3 Hospital & Diagnostic Laboratories

                7.5 By Geography

                                7.5.1 North America

                                                7.5.1.1 United States

                                                7.5.1.2 Canada

                                                7.5.1.3 Mexico

                                7.5.2 Europe

                                                7.5.2.1 France

                                                7.5.2.2 United Kingdom

                                                7.5.2.3 Germany

                                                7.5.2.4 Italy

                                                7.5.2.5 Spain

                                                7.5.2.6 Rest of Europe

                                7.5.3 Asia-Pacific (APAC)

                                                7.5.3.1 India

                                                7.5.3.2 China

                                                7.5.3.3 Japan

                                                7.5.3.4 Australia

                                                7.5.3.5 South Korea

                                                7.5.3.6 Rest of Asia-Pacific

                                7.5.4 Middle East & Africa (MEA)

                                                7.5.4.1 GCC

                                                7.5.4.2 South Africa

                                                7.5.4.3 Rest of Middle East & Africa

                                7.5.5 South America

                                                7.5.5.1 Brazil

                                                7.5.5.2 Argentina

                                                7.5.5.3 Rest of South America

8. Company Profiles & Competitive Landscape

                8.1 Abcam Plc

                8.2 Becton Dickinson & Company

                8.3 Bio-Rad Laboratories

                8.4 Biotek Instruments

                8.5 Biotium

                8.6 Creative Bioarray

                8.7 Danaher Corporation

                8.8 GE Healthcare

                8.9 Merck KGaA

                8.10 Perkin Elmer

                8.11 Promega Corporation

                8.12 Thermo Fischer Scientific Inc.

                *List Not Exhaustive

9. Future of the Market

Purchase Report

Our Clients Include View All

Looking to Customize Report?